Pacific Biosciences Of California (PACB) Price to Sales (2010 - 2026)

Pacific Biosciences Of California has reported Price to Sales for 17 years, with the latest figure at 13.39 in Q2 2026.

• On a quarterly basis, Price to Sales rose 42.93% year-over-year to 13.39 in Q2 2026; TTM through Jun 2026 was 3.28, a 37.42% increase from a year earlier, with the FY2025 full-year figure at 3.53, up 0.88% from the prior year.
• Price to Sales was 13.39 for Q2 2026 at Pacific Biosciences Of California, up from 11.02 in the prior quarter.
• The five-year high for Price to Sales was 74.36 in Q1 2023, with the low at 9.37 in Q2 2025.
• Average Price to Sales over 5 years is 30.78, with a median of 20.02 recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Price to Sales sank 87.67% in 2022, then soared 150.0% in 2023.
• Over 5 years, Price to Sales stood at 67.74 in 2022, then tumbled by 33.55% to 45.01 in 2023, then sank by 69.48% to 13.74 in 2024, then decreased by 7.92% to 12.65 in 2025, then increased by 5.84% to 13.39 in 2026.
• The last three Price to Sales figures came in at 13.39 (Q2 2026), 11.02 (Q1 2026), and 12.65 (Q4 2025), per Business Quant data.